SCHEMBL20827746

SCHEMBL20827746

CSCC[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CCCCCCCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 9/20 0.50
▸ NPY5R Q15761 6/20 0.50
▸ NPY1R P25929 5/20 0.50
▸ NPY2R P49146 3/20 0.50
▸ FNTA P49354 3/20 0.48
▸ FNTB P49356 3/20 0.48
▸ PGGT1B P53609 1/20 0.46
▸ TLR2 O60603 1/20 0.44
▸ TACR3 P29371 1/20 0.42
▸ SIRT5 Q9NXA8 1/20 0.42
▸ GRPR P30550 1/20 0.41
▸ IL23R Q5VWK5 1/20 0.41
▸ CCKBR P32239 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31157753 0.96 TLR2 (0.49) NPY4RNPY5RNPY1RNPY2RFNTA
SCHEMBL31157653 0.92 TLR2 (0.56) NPY4RNPY5RNPY1RNPY2RFNTA
SCHEMBL31157714 0.92 NPY5R (0.51) NPY4RNPY5RNPY1RNPY2RFNTA
SCHEMBL20827674 0.92 NPY4R (0.45) NPY4RNPY5RNPY1RNPY2RFNTA
SCHEMBL31157760 0.90 SIRT5 (0.53) NPY4RNPY5RNPY1RNPY2RTACR3
SCHEMBL30168004 0.90 SIRT5 (0.53) NPY4RNPY5RNPY1RNPY2RTACR3
SCHEMBL30998021 0.90 SIRT5 (0.53) NPY4RNPY5RNPY1RNPY2RTACR3
SCHEMBL12066140 0.90 SIRT5 (0.53) NPY4RNPY5RNPY1RNPY2RTACR3
SCHEMBL31157647 0.90 SIRT5 (0.53) NPY4RNPY5RNPY1RNPY2RTACR3
SCHEMBL30051231 0.90 SIRT5 (0.53) NPY4RNPY5RNPY1RNPY2RTACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019054822-A1 ACTIVE SUBSTANCE-HEXAPEPTIDE COMPLEX AND COSMETIC COMPOSITION CONTAINING SAME 애니젠 주식회사 2019-03-21 — — WO disclosed
Send feedback